Metformin reshapes the tumor microenvironment and enhances prognosis in invasive pancreatic ductal adenocarcinoma with diabetes mellitus.

Additionally, the metformin group showed a trend toward a higher pathological response rate to neoadjuvant chemotherapy, although this difference did not reach statistical significance (23.5% vs. 8.3%, P=0.17).

also in 53,322 other papers

The impact of metformin intake on patient outcome Among the 65 diabetic patients, there was a trend toward shorter RFS and OS compared to non-diabetic patients; however, these differences did not reach statistical significance ( Figure 1 ).

also in 111,027 other papers